516 related articles for article (PubMed ID: 17719511)
1. Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries.
Rigler SK; Shireman TI; Kallenbach L
Am J Geriatr Pharmacother; 2007 Jun; 5(2):91-9. PubMed ID: 17719511
[TBL] [Abstract][Full Text] [Related]
2. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
Shireman TI; Rigler SK
Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
5. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
6. Rates of adverse events of long-acting opioids in a state Medicaid program.
Hartung DM; Middleton L; Haxby DG; Koder M; Ketchum KL; Chou R
Ann Pharmacother; 2007 Jun; 41(6):921-8. PubMed ID: 17504834
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
11. National utilization of transdermal fentanyl among community-dwelling older people in Finland.
Bell JS; Klaukka T; Ahonen J; Hartikainen S
Am J Geriatr Pharmacother; 2009 Dec; 7(6):355-61. PubMed ID: 20129256
[TBL] [Abstract][Full Text] [Related]
12. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
13. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
14. Side effects of opioids during short-term administration: effect of age, gender, and race.
Cepeda MS; Farrar JT; Baumgarten M; Boston R; Carr DB; Strom BL
Clin Pharmacol Ther; 2003 Aug; 74(2):102-12. PubMed ID: 12891220
[TBL] [Abstract][Full Text] [Related]
15. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain.
Gallagher RM; Welz-Bosna M; Gammaitoni A
Pain Med; 2007; 8(1):71-4. PubMed ID: 17244106
[TBL] [Abstract][Full Text] [Related]
16. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients.
Weschules DJ; Bain KT; Reifsnyder J; McMath JA; Kupperman DE; Gallagher RM; Hauck WW; Knowlton CH
Pain Med; 2006; 7(4):320-9. PubMed ID: 16898943
[TBL] [Abstract][Full Text] [Related]
17. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine.
Kalso E; Simpson KH; Slappendel R; Dejonckheere J; Richarz U
BMC Med; 2007 Dec; 5():39. PubMed ID: 18154644
[TBL] [Abstract][Full Text] [Related]
18. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
19. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system.
Kosinski MR; Schein JR; Vallow SM; Ascher S; Harte C; Shikiar R; Frank L; Margolis MK; Vorsanger G
Curr Med Res Opin; 2005 Jun; 21(6):849-62. PubMed ID: 15969885
[TBL] [Abstract][Full Text] [Related]
20. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
